Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeted Gene Editing of Glia Maturation Factor in Microglia: a Novel Alzheimer’s Disease Therapeutic Target
Sudhanshu P. Raikwar, Ramasamy Thangavel, Iuliia Dubova, et al.
Molecular Neurobiology (2018) Vol. 56, Iss. 1, pp. 378-393
Open Access | Times Cited: 58

Showing 1-25 of 58 citing articles:

Mast Cells in Stress, Pain, Blood-Brain Barrier, Neuroinflammation and Alzheimer’s Disease
Duraisamy Kempuraj, Shireen Mentor, Ramasamy Thangavel, et al.
Frontiers in Cellular Neuroscience (2019) Vol. 13
Open Access | Times Cited: 111
CRISPR/Cas9 gene editing: New hope for Alzheimer's disease therapeutics
Shanu Bhardwaj, Kavindra Kumar Kesari, Mahesh Rachamalla, et al.
Journal of Advanced Research (2021) Vol. 40, pp. 207-221
Open Access | Times Cited: 73
Delivering the Promise of Gene Therapy with Nanomedicines in Treating Central Nervous System Diseases
Meihua Luo, Leo Kit Cheung Lee, Bo Peng, et al.
Advanced Science (2022) Vol. 9, Iss. 26
Open Access | Times Cited: 43
An Update on the Application of CRISPR Technology in Clinical Practice
Firouzeh Morshedzadeh, Mahmoud Ghanei, Malihe Lotfi, et al.
Molecular Biotechnology (2023) Vol. 66, Iss. 2, pp. 179-197
Open Access | Times Cited: 23
Gene Therapy Approach with an Emphasis on Growth Factors: Theoretical and Clinical Outcomes in Neurodegenerative Diseases
Della Grace Thomas Parambi, Khalid Saad Alharbi, Rajesh Kumar, et al.
Molecular Neurobiology (2021) Vol. 59, Iss. 1, pp. 191-233
Open Access | Times Cited: 43
Recent advances in lentiviral vectors for gene therapy
Xiaoyu Wang, Cuicui Ma, Roberto Rodríguez‐Labrada, et al.
Science China Life Sciences (2021) Vol. 64, Iss. 11, pp. 1842-1857
Closed Access | Times Cited: 43
CRISPR-Cas9: A Promising Genome Editing Therapeutic Tool for Alzheimer’s Disease—A Narrative Review
Nirmal Chandra Barman, Md. Niuz Morshed Khan, Maidul Islam, et al.
Neurology and Therapy (2020) Vol. 9, Iss. 2, pp. 419-434
Open Access | Times Cited: 45
Characteristics and advantages of adeno-associated virus vector-mediated gene therapy for neurodegenerative diseases
Rui Li, Yuan Qu, Yi Liu, et al.
Neural Regeneration Research (2019) Vol. 14, Iss. 6, pp. 931-931
Open Access | Times Cited: 44
CRISPR-Cas9-Mediated Gene Therapy in Neurological Disorders
Lihong Guan, Yawei Han, Ciqing Yang, et al.
Molecular Neurobiology (2021) Vol. 59, Iss. 2, pp. 968-982
Closed Access | Times Cited: 39
Application of CRISPR/Cas9 in Alzheimer’s Disease
Likui Lu, Yu Xi, Yongle Cai, et al.
Frontiers in Neuroscience (2021) Vol. 15
Open Access | Times Cited: 38
Application of CRISPR/Cas9 System in the Treatment of Alzheimer’s Disease and Neurodegenerative Diseases
Araz Rahimi, Parsa Sameei, Sana Mousavi, et al.
Molecular Neurobiology (2024) Vol. 61, Iss. 11, pp. 9416-9431
Closed Access | Times Cited: 5
Editing the Central Nervous System Through CRISPR/Cas9 Systems
Agustín Cota-Coronado, Néstor Fabián Díaz-Martínez, Eduardo Padilla‐Camberos, et al.
Frontiers in Molecular Neuroscience (2019) Vol. 12
Open Access | Times Cited: 37
CRISPR/Cas9 novel therapeutic road for the treatment of neurodegenerative diseases
Ansar Karimian, Negar Gorjizadeh, Forough Alemi, et al.
Life Sciences (2020) Vol. 259, pp. 118165-118165
Closed Access | Times Cited: 37
Mast Cell Activation, Neuroinflammation, and Tight Junction Protein Derangement in Acute Traumatic Brain Injury
Duraisamy Kempuraj, Mohammad Ejaz Ahmed, Govindhasamy Pushpavathi Selvakumar, et al.
Mediators of Inflammation (2020) Vol. 2020, pp. 1-12
Open Access | Times Cited: 36
Acute Traumatic Brain Injury-Induced Neuroinflammatory Response and Neurovascular Disorders in the Brain
Duraisamy Kempuraj, Mohammad Ejaz Ahmed, Govindhasamy Pushpavathi Selvakumar, et al.
Neurotoxicity Research (2020) Vol. 39, Iss. 2, pp. 359-368
Open Access | Times Cited: 36
Emerging technologies to study glial cells
Hélène Hirbec, Nicole Déglon, Lynette C. Foo, et al.
Glia (2020) Vol. 68, Iss. 9, pp. 1692-1728
Open Access | Times Cited: 34
The Neuroprotective Effect of Byu d Mar 25 in LPS-Induced Alzheimer's Disease Mice Model
Lan Liu, Yongcang Zhang, Liang Tang, et al.
Evidence-based Complementary and Alternative Medicine (2021) Vol. 2021, pp. 1-12
Open Access | Times Cited: 30
In vivo production of CAR T cell: Opportunities and challenges
Zhiqiang Song, Yitong Zhou, Binbin Wang, et al.
Genes & Diseases (2025), pp. 101612-101612
Open Access
CRISPR/Cas9-Based therapeutics as a promising strategy for management of Alzheimer’s disease: progress and prospects
Mohamad Sultan Khan, Nousheen Qureshi, Rehan Khan, et al.
Frontiers in Cellular Neuroscience (2025) Vol. 19
Open Access
Glia Maturation Factor and Mast Cell-Dependent Expression of Inflammatory Mediators and Proteinase Activated Receptor-2 in Neuroinflammation
Duraisamy Kempuraj, Govindhasamy Pushpavathi Selvakumar, Ramasamy Thangavel, et al.
Journal of Alzheimer s Disease (2018) Vol. 66, Iss. 3, pp. 1117-1129
Open Access | Times Cited: 34
Next Generation Precision Medicine: CRISPR-mediated Genome Editing for the Treatment of Neurodegenerative Disorders
Sudhanshu P. Raikwar, Nidhi S. Kikkeri, Ragha Sakuru, et al.
Journal of Neuroimmune Pharmacology (2019) Vol. 14, Iss. 4, pp. 608-641
Open Access | Times Cited: 32
Genetic Variants and Oxidative Stress in Alzheimer’s Disease
Marta Kowalska, Katarzyna Wize, Michał Prendecki, et al.
Current Alzheimer Research (2020) Vol. 17, Iss. 3, pp. 208-223
Closed Access | Times Cited: 31
Innovations advancing our understanding of microglia in Alzheimer's disease: From in vitro to in vivo models
Simon Maksour, Lezanne Ooi
Journal of Neurochemistry (2023) Vol. 166, Iss. 3, pp. 497-516
Open Access | Times Cited: 9
Nanotechnology-based delivery for CRISPR-Cas 9 cargo in Alzheimer's disease
Shruti Rawal, Akruti Khodakiya, Bhupendra G. Prajapati
Elsevier eBooks (2024), pp. 139-152
Closed Access | Times Cited: 3
CRISPR-Cas9 in Alzheimer’s disease: Therapeutic trends, modalities, and challenges
Leena Chacko, Anupama Chaudhary, Birbal Singh, et al.
Drug Discovery Today (2023) Vol. 28, Iss. 8, pp. 103652-103652
Closed Access | Times Cited: 8
Page 1 - Next Page

Scroll to top